推荐产品
化驗
99%
形狀
foil
製造商/商標名
Goodfellow 457-233-26
電阻係數
54 μΩ-cm
尺寸 × 厚度
50 x 50 mm × 0.1 mm
bp
3464 °C (lit.)
mp
920 °C (lit.)
密度
6.19 g/mL at 25 °C (lit.)
SMILES 字串
[La]
InChI
1S/La
InChI 密鑰
FZLIPJUXYLNCLC-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
For updated SDS information please visit www.goodfellow.com.
法律資訊
Product of Goodfellow
儲存類別代碼
4.3 - Hazardous materials which set free flammable gases upon contact with water
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
The International journal of artificial organs, 30(4), 293-300 (2007-05-24)
Phosphate overload is a dramatic consequence in end-stage renal disease (ESRD) patients. Recent studies have well documented that abnormalities in mineral and bone metabolism in these patients are associated with increased cardiovascular morbidity and mortality. Elevated serum phosphate and calcium-phosphate
Gadolinium and lanthanum: a iatrogenic transmetallation?
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门